OK, by "substantial" news I meant any indication on the outcome of the Phase 3. "Supply and Demand" is a reasonable riposte, but using it as the reason for a rising stock price is a little redundant.
Mostly, I'm thinking of Amarin before its Top Line. That stock moved up and down a lot, but the net result was flat, and Vascepa's Phase 3 was pretty much a re-run of another that it passed years earlier.